Mifepristone
- PDF / 171,726 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 59 Downloads / 139 Views
1
S
Various toxicities: case report A 57-year-old woman developed hypokalaemia, fluid overload, metabolic alkalosis and elevated thyrotropin level secondary to drug toxicity during treatment with mifepristone for Cushing’s syndrome. The woman, who had type 2 diabetes mellitus and Cushing’s syndrome, started receiving treatment with mifepristone 300mg for Cushing’s syndrome, which was then increased to 600mg daily and later to 900mg daily over 3 months [route not stated]. A few weeks later, she was admitted to the ICU due to severe hypokalaemia, fluid overload, metabolic alkalosis and increased thyrotropin, which were consistent with mifepristone toxicity. The woman’s treatment with mifepristone was held, and she was discharged. Two weeks after discharge she was followed up as an outpatient. The treatment with mifepristone was discontinued. Laboratory investigation showed normal potassium level. She was treated with dulaglutide, insulin degludec and metformin for diabetes. Author comment: "In summary, the patient presented with volume overload, hypokalemia, metabolic alkalosis and elevated thyrotropin levels, all consistent with mifepristone toxicity." Katta S, et al. Hypokalemia associated with mifepristone use in the treatment of cushing’s syndrome. Endocrinology, Diabetes and Metabolism Case Reports 2019: No. 1, 12 Nov 2019. Available from: URL: http://doi.org/10.1530/EDM-19-0064 803443762 USA
»
Editorial comment: Details of this case report have previously been published and processed for Adis PV [see Reactions 1712 p365; 803335674].
0114-9954/20/1785-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 4 Jan 2020 No. 1785
Data Loading...
